CFCM INTELLIGENCE

Understand what changes.
Know what is established.

Technology, reagents, companies and regulation — tracked through dated events, primary sources and explicit evidence boundaries.

Technology Watch

Platforms, software and changing capabilities.

Reagent Watch

Clones, formats, intended use and availability.

Company Watch

Portfolios, partnerships and market presence.

Regulatory Watch

Primary documents, jurisdictions and effective dates.

Published signals

Only records released through the current editorial workflow appear here. Dates describe the underlying event and source, not the date CFCM discovered it. Independent scientific review is not implied unless explicitly stated.

No market records have completed editorial review yet.

Regulatory

BD OneFlow LST and B-CLPD T1 receive FDA 510(k) clearance: what K260215 actually covers

FDA cleared BD OneFlow LST and B-CLPD T1 for specified FACSLyric use as a qualitative diagnostic aid. K260215 does not establish an MRD indication.

Event date

October 20, 2026

Source publication date

October 20, 2026

United States

FDA 510(k) K260215, Class II: BD OneFlow LST and B-CLPD T1 for the indicated FACSLyric/FACSuite Clinical setup. BD remains legal manufacturer while Waters completes regulatory transfer. Preorders announced 10 November; U.S. general availability planned spring 2027. No separate MRD indication or new IVDR clearance inferred.

Read the evidence →

fda-clears-bd-oneflow-lst-bclpd-t1-k260215-2026

Technology

ROR1 heterogeneity in mantle cell lymphoma: what 15 flow-cytometry cases show

Wang et al. report heterogeneous ROR1 expression in 15 primary MCL flow-cytometry cases (5 minimal/undetectable, 7 dim, 3 moderate), with time/compartment variation and experimental mechanistic evidence. Expression categories are descriptive, not validated diagnostic cutoffs or proof of clinical treatment response.

Event date

October 14, 2026

Source publication date

October 14, 2026

Published experimental study; no validated clinical ROR1 flow assay, clinical cutoff or CE-IVD/FDA authorisation for an MCL ROR1-directed indication established.

Read the evidence →

ror1-expression-heterogeneity-mantle-cell-lymphoma-flow-2026-10-14

Company

Partillion Nanovials joins USC CAR-T single-cell potency research: proposed, not validated

Partillion announced that Nanovials will support an USC-led, CIRM-funded CAR-T single-cell research programme combining high-dimensional flow and Cell-Cell-seq. CIRM independently confirms award DISC5-19893 ($2,499,738) but lists it Pre-Active. No assay-performance results or clinical validation have been reported.

Event date

October 14, 2026

Source publication date

October 14, 2026

announced research programme; CIRM award Pre-Active; NOT a CE-IVD/FDA clinical potency test or approved clinical assay

Read the evidence →

partillion-cirm-car-t-potency-nanovials-research-2026-10-14

Regulatory

FDA codifies Class II hematopoietic cell enrichment kit category; De Novo decision dates to 2023

FDA codified hematopoietic cell enrichment kits as Class II under 21 CFR 866.6120 on 9 October 2026, following the original 2023 De Novo classification. This is a pre-analytical device category, not a new MRD assay authorization.

Event date

October 9, 2026

Source publication date

October 9, 2026

United States

Class II with special controls; 2023 De Novo classification codified in 2026.

Read the evidence →

fda-hematopoietic-cell-enrichment-class-ii-codification-2026-10-09

Technology

Fresh bone-lesion flow cytometry supports Langerhans cell histiocytosis in two pediatric cases

Two pediatric LCH case reports describe flow cytometry on fresh bone-lesion tissue alongside pathology. This offers early feasibility evidence, without establishing diagnostic sensitivity or replacing integrated diagnosis.

Event date

October 8, 2026

Source publication date

October 8, 2026

Pediatric case series

Clinical research report; no regulatory authorization established.

Read the evidence →

pediatric-osseous-lch-fresh-tissue-flow-cytometry-2026-10-08

Company

CyPath Lung passes 1,620 tests through Q3 2026 as bioAffinity reports more than 100% year-on-year sales growth

bioAffinity Technologies reported on 6 October 2026 that CyPath Lung testing exceeded 1,620 tests through Q3 2026 versus 775 through Q3 2025, with the test marketed in the United States as a laboratory-developed test using flow cytometry and proprietary AI.

Event date

October 6, 2026

Source publication date

October 6, 2026

United States

COMMERCIALLY AVAILABLE in the United States as a Laboratory Developed Test (LDT) through Precision Pathology Laboratory Services. The cited source does not establish FDA clearance or approval of CyPath Lung as an IVD device.

Read the evidence →

cypath-lung-q3-2026-adoption-flow-ai-ldt

Technology

ARUP scales EventHorizon foundation-model research for clinical flow cytometry on Utah's Redtail AI Factory

ARUP Laboratories was selected on 6 October 2026 for a Redtail AI Factory challenge project to scale EventHorizon, a self-supervised foundation-model framework trained from approximately 100,000 de-identified clinical flow-cytometry cases.

Event date

October 6, 2026

Source publication date

October 6, 2026

Utah, USA; clinical flow-cytometry research

ANNOUNCED research/development project. EventHorizon is not presented in the cited sources as an FDA-cleared/approved diagnostic product or as clinically deployed autonomous software.

Read the evidence →

arup-eventhorizon-redtail-foundation-model-clinical-flow-2026-10-06

Technology

Dual QC and pre-analytics shape longitudinal spectral cytometry: 2026 cohort study

A longitudinal spectral cytometry study uses rainbow-bead and single-stain spectral controls to distinguish instrument and reagent anomalies. The evidence supports troubleshooting within the studied setup, with broader transferability still to be tested.

Event date

October 5, 2026

Source publication date

October 5, 2026

Research setting

Research method; no new clinical device authorization established.

Read the evidence →

longitudinal-spectral-flow-dual-qc-pacmap-gosling-2026-10-05

Company

CellCarta and Waters form a flow-cytometry companion-diagnostics partnership

CellCarta and Waters announced a strategic partnership on 5 October 2026 to pursue flow-cytometry companion-diagnostic and next-generation cytometry programs with biopharma sponsors.

Event date

October 5, 2026

Source publication date

October 5, 2026

Global; explicit China/global program component

Strategic partnership announced. No specific companion diagnostic is presented as FDA cleared/approved or CE-IVD by this announcement.

Read the evidence →

cellcarta-waters-flow-cytometry-companion-diagnostics-2026-10-05

Company

Standard BioTools signs agreement to sell Microfluidics business to ARCHIMED; closing remains pending

Standard BioTools signed a definitive agreement on 5 October 2026 to sell its Microfluidics business to ARCHIMED. Closing is expected in approximately 30 days but has not occurred.

Event date

October 5, 2026

Source publication date

October 5, 2026

United States; global life-science research market

Definitive agreement signed; NOT CLOSED. Expected to close in approximately 30 days subject to customary closing conditions.

Read the evidence →

standard-biotools-microfluidics-sale-archimed-2026-10-05

Reagent

Rarity moves superRCA KIT D816V and JAK2 V617F into the current RUO catalogue

Rarity Bioscience's current research-use catalogue lists Ultra-Sensitive KIT D816V and JAK2 V617F superRCA mutation kits with flow-cytometer readout.

Event date

October 5, 2026

Source publication date

Sweden / global research market

Research Use Only (RUO) available; no diagnostic authorization inferred from the cited sources.

Read the evidence →

rarity-superrca-kit-d816v-jak2-ruo-2026-10-05

Technology

Beckman Coulter brings a multicentre spectral AML MRD harmonisation initiative to ICCS 2026

Beckman Coulter's ICCS 2026 program scheduled a workshop for 4 October on an international initiative evaluating spectral flow cytometry for AML MRD research. Its stated aims include workflow harmonisation, standardized acquisition and analysis, and multicentre implementation. The program listing does not establish completed presentation or multicentre performance.

Event date

October 4, 2026

Source publication date

International collaboration; ICCS 2026, Miami, USA

Research/clinical-research initiative; no new product authorization or diagnostic approval established by the event page.

Read the evidence →

beckman-spectral-aml-mrd-harmonisation-iccs-2026

Company

Waters Biosciences brings the former BD flow portfolio to ICCS 2026 under its new division

ICCS 2026 is the first ICCS meeting after Waters completed its February 2026 combination with BD's Biosciences & Diagnostic Solutions businesses. Waters Biosciences is now presenting the flow cytometry portfolio as a connected stack spanning routine clinical flow, spectral analysis, imaging flow, sample preparation, reagents and software.

Event date

October 4, 2026

Source publication date

United States event; global Waters Biosciences portfolio

Waters completed the combination with BD's Biosciences & Diagnostic Solutions businesses on 9 February 2026. ICCS 2026 materials present the flow portfolio under Waters Biosciences. No new CE-IVD or FDA authorization is inferred from conference branding.

Read the evidence →

waters-biosciences-iccs-2026-flow-portfolio

Technology

Agilent launches NovoStation to automate flow-cytometry sample preparation

Agilent launched the NovoStation Sample Preparation System on 1 October 2026, automating reagent cocktailing, staining, washing and other flow-cytometry sample-preparation steps and linking with compatible NovoCyte instruments.

Event date

October 1, 2026

Source publication date

October 1, 2026

Commercial product page available through Agilent; specific country-by-country availability is not stated in the cited launch

Commercially offered via Agilent Request Quote in the Research Flow Cytometry portfolio. No CE-IVD or FDA diagnostic authorization identified in the cited primary sources.

Read the evidence →

agilent-novostation-flow-cytometry-automation-2026-10-01

Company

Standard BioTools switches mass cytometry buyer to Element; agreement signed, closing still pending

Standard BioTools terminated its planned sale of the Mass Cytometry Business to Multiplex Bio and signed a new definitive $5.5 million cash agreement with Element Biosystems, an acquisition vehicle formed by GMT Venture Partners. The transaction has not closed.

Event date

September 30, 2026

Source publication date

September 30, 2026

United States; global mass-cytometry customer base

Definitive sale agreement signed; NOT CLOSED. Expected by end-2026, subject to stockholder approval and other customary closing conditions.

Read the evidence →

standard-biotools-mass-cytometry-sale-element-2026-09-30

Technology

Agilent adds AI cell identification and segmentation to BioTek Gen5 imaging workflows

Agilent launched the BioTek Gen5 AI Cell Identification Module on 29 September 2026. The add-on brings AI-based cell identification and segmentation to compatible Cytation and Lionheart automated imaging systems, targeting research workflows rather than clinical diagnosis.

Event date

September 29, 2026

Source publication date

September 29, 2026

Global life-science and pharmaceutical research market; country-specific availability not established in the cited release

Product launch announced for compatible Agilent BioTek automated imaging systems. Research/life-science positioning; no CE-IVD or FDA diagnostic authorization identified in the cited source.

Read the evidence →

agilent-gen5-ai-cell-identification-2026-09-29

Technology

Leica Autiva Spatial Phenotyper: Workflow, Evidence and Limits

Leica Autiva combines cyclic staining, multiplex imaging and AI analysis for spatial phenotyping. Review its workflow, manufacturer claims and limits for clinical flow cytometry.

Event date

September 28, 2026

Source publication date

September 28, 2026

Global research market via Leica Microsystems and authorized partners

Commercially available through Leica Microsystems and authorized partners for spatial-biology research. No clinical IVD authorization is established by the cited launch source.

Read the evidence →

leica-autiva-spatial-phenotyper-2026-09-28

Technology

NIST shows cross-platform TBMNK standardisation across 42 cytometers and 21 sites

A NIST-coordinated interlaboratory study standardized a human TBMNK assay across 42 cytometers from 7 manufacturers at 21 sites, reporting cell counts and fluorescence in quantitative, traceable units and producing an AI-ready reference dataset.

Event date

September 28, 2026

Source publication date

September 28, 2026

International; 21 participating sites

Published research and standardisation framework; not a regulatory standard and not an IVD authorization.

Read the evidence →

nist-tbmnk-standardisation-ai-ready-2026-09-28

Technology

When QC passes but cytometer stability changes: FlowCytoMonitoR

A passing daily QC result does not tell the whole story. A critical look at FlowCytoMonitoR, its longitudinal QC case studies, and the limits of failure prediction.

Event date

September 26, 2026

Source publication date

September 26, 2026

Published research software. Neither CE-IVD nor FDA authorisation for clinical diagnostic decisions is established. No product-launch or device regulatory milestone asserted.

Read the evidence →

flowcytomonitor-longitudinal-qc-across-cytometers-2026-09-26

Company

Slingshot clarifies non-U.S. distribution model for SpectraComp

Slingshot Bio's DGfZ 2026 page states that SpectraComp does not ship outside the U.S. and that non-U.S. customers are served through distributors. No Spain-specific distributor is identified.

Event date

September 25, 2026

Source publication date

Non-U.S. markets; Europe signal from DGfZ event page. Spain-specific availability not verified.

Manufacturer states SpectraComp does not ship outside the U.S. and works through distributors internationally. Country-specific availability and regulatory status must be confirmed separately.

Read the evidence →

slingshot-spectracomp-non-us-distributors-2026-09-25

Technology

Cytek Cloud adds browser-based analysis, extending the RUO workflow from panel design to downstream review

Cytek has added Cloud Analysis to Cytek Cloud, allowing researchers to continue analysis from SpectroFlo data with plots and gates preserved. Cytek Cloud Premium includes Cloud Analysis and cloud data storage and is explicitly labelled Research Use Only.

Event date

September 23, 2026

Source publication date

September 23, 2026

United States for the new Cloud Analysis/Premium launch; broader Cytek Cloud ecosystem exists internationally

Cytek Cloud Premium with Cloud Analysis is commercially offered in the U.S. and is explicitly Research Use Only; not for use in diagnostic or therapeutic procedures.

Read the evidence →

cytek-cloud-analysis-2026-09-23

Technology

Four-channel impedance cytometry separates overlapping events; clinical allergy testing is unvalidated

Lee and Tang demonstrated a four-channel, code-multiplexed impedance-cytometry proof of concept. Synthetic waveform decoding reached 99.85%, 96.93% and 88.83% for single, double and triple overlaps; these are not diagnostic accuracy figures. A six-donor basophil activation pilot remains preliminary.

Event date

September 21, 2026

Source publication date

September 21, 2026

USA

Peer-reviewed research proof of concept / WATCH; no demonstrated clinical diagnostic authorization, CE-IVD or FDA clearance/approval.

Read the evidence →

four-channel-impedance-cytometry-demonstrates-experimental-basophil-activation-profiling

Technology

FlowJo 10.10.2 brings FACSDiscover detector-independent scaling into downstream analysis

FlowJo v10.10.2, released 18 September 2026, adds support for FACSDiscover Detector Independent Scaling data and makes BD SpectralFX the default unmixing method for FACSDiscover data.

Event date

September 18, 2026

Source publication date

September 18, 2026

Global software user base

FlowJo v10.10.2 software update released. The cited release notes do not establish a clinical IVD authorization; none is inferred here.

Read the evidence →

flowjo-10-10-2-dsi-facsdiscover-2026-09-18

FACSDiscover A7 — commercial launch and evidence limits

Waters announced FACSDiscover A7 commercial availability in September 2026. The research-use-only spectral analyzer combines automated instrument setup/QC and downstream spectral analysis. Reported reproducibility figures come from manufacturer testing, not independent clinical assay validation.

Event date

September 14, 2026

Source publication date

Global launch announcement; local availability may vary

Commercially available, RUO. No CE-IVD or FDA diagnostic authorization inferred.

Read the evidence →

facsdiscover-a7-commercial-launch-evidence-2026

TECHNOLOGY WATCH

From specifications to useful performance

Announcements, independent evidence and clinical validation are assessed separately.

Read the CFCM analysis →

REAGENT WATCH

Reagents in clinical context

Identity, clone, catalogue number and jurisdiction matter when interpreting a product update.

Explore antibody selection →

COMPANY WATCH

Market presence needs evidence

A distributor listing, a conference presentation and clinical authorisation describe different developments.

Read the market analysis →

REGULATORY WATCH

Start with intended purpose

Track the authority, document, jurisdiction and effective date before drawing operational conclusions.

Read the regulatory analysis →

How CFCM evaluates a signal

Primary evidence → What it demonstrates → Evidence boundary → Practical implications → CFCM view.

Manufacturer statements are identified as such. Unknown dates and unconfirmed availability remain unknown. Editorial priority is separate from publication approval.

Editor, affiliation and independence →

From a development to a laboratory question

Use the clinical resources to test the interpretation behind a technology or reagent claim. Discuss defined technical content or a disclosed sponsorship brief when appropriate.